Is there clinical data showing the efficacy of Sorbact versus antibiotics specifically for MRSA?

There are two aspects to consider: 1) the comparison of Sorbact® with topical antibiotic treatment and 2) the comparison with systemic antibiotic treatment.

With regard to 1) the comparison of Sorbact® with topical antibiotic treatment: in general, topical antibiotic treatment of wounds is not standard of care and several publications show that the efficacy of topical antibiotics is limited and the risk of resistance increases significantly. There is a publication by Dwiyana et al comparing both in infected wounds of epidermolysis bullosa, which shows that Sorbact® promotes faster wound closure compared to topical antibiotic treatment.

In terms of 2) the comparison with systemic antibiotics: A comparison between Sorbact and systemic antibiotics is not possible as Sorbact can never replace systemic antibiotic treatment when indicated. When localised wound infections develop into disseminated infections, systemic antibiotics are mandatory according to guidelines. However, early use of Sorbact may avoid the need for systemic antibiotics. In general, keeping the bacterial load low reduces the risk of serious infection. As Stanirowski showed in 2016 and 2019, the use of Leukomed Sorbact in caesarean sections reduces the risk of surgical site infections and the need for systemic antibiotic treatment. There is also in vitro evidence of Sorbact’s ability to bind multi-resistant bacteria.